Skip to content
TDIA
Menu

Practice type

This is a medical visit before it is an aesthetic appointment.

Before booking a same-day treatment, name the clinician who assesses candidacy, the person authorized to perform it, the real escalation plan, and the record that will explain what happened.

An open medical building shows an exam room, group workroom, procedure room, and telehealth office

A cosmetic treatment may look like a retail service, but a prescription drug or medical device turns it into a patient-care pathway. The physician's first responsibility is not to complete a treatment menu. It is to establish candidacy, clinician authority, product or device choice, consent, and a plan for the complication that changes the patient's day.

Put each service in its clinical lane

Do not use "injector" as a scope analysis. For every service, identify the assessment and ordering authority, the person who performs it, the relevant training and documented competency, the supervision or practice structure, the setting, and the escalation plan.

ServiceQuestions to answer before treatment
Prescription injectionWho performs the appropriate prior assessment, what product and indication are used, and who can respond to a complication?
Dermal fillerWhat is the approved labeling or intended use, body area, injection plan, vascular-event response, and referral path?
Laser or IPLWhat device model and indicated use apply, who is trained to operate it, and is the required physician availability and emergency plan real?
Compounded productWhat is the formulation, source, storage and lot workflow, and what patient-specific use is proposed?
Mobile or event treatmentCan the same assessment, product custody, record access, clinician support, and escalation plan function at that site?

The Medical Board's cosmetic-treatment guidance is procedure-specific. For cosmetic Botox, it says an MA may not inject, while a physician, supervised RN, or supervised PA may do so under the described rules. Laser and IPL work also has distinct practitioner and supervision rules. Do not generalize one procedure's answer to every medication or device. Confirm the actual product, procedure, license, order, setting, and current Board guidance.

A spa brand cannot make medical judgments

California does not permit unlicensed persons or entities to practice medicine or control professional clinical judgment. A management company can support administration. It cannot decide candidacy, product selection, clinical protocols, clinician competency, medical-record control, or the clinical response to a complication.

Map the medical practice, MSO, retail company, property owner, device owner, and trade name. Identify who employs or contracts with clinicians, holds records, buys and stores product, selects devices, and bills for care. This is not a universal ownership formula; it is a practical test of whether a nonclinical company has acquired control over medical decisions.

Make the treatment plan product and anatomy specific

The clinical record should let the next clinician understand what happened without guessing. Record the assessment, relevant alternatives and consent discussion, product or device, product source and lot where applicable, dose or amount, body area and treatment diagram, technique or device settings, operator, patient instructions, follow-up, and complication contact route.

FDA status is product- and use-specific. Drugs may be approved, while aesthetic devices may be cleared, approved, or authorized for particular intended uses. Verify the current labeling and instructions for use for the actual model and product. Off-label use is not automatically improper, but it changes the physician's evidence, consent, and policy-review questions.

For fillers, FDA identifies accidental intravascular injection as a serious risk that can cause tissue necrosis, vision injury or blindness, or stroke. The agency also states that needle-free filler injection devices are not approved. A complication plan is therefore part of candidacy, not an afterthought: stop treatment, recognize the event, begin the prepared response within the practice's competence, escalate promptly, and support the patient after hours.

Make safe injection technique visible

CDC safe-injection guidance says never reuse a needle or syringe and not to administer a single-dose or single-use vial, ampule, bag, or bottle to more than one patient. Prepare medication in a clean area and use controlled procedures for multidose vials. Connect that work to lot and recall traceability, storage, handling, waste, and infection-control records.

Do not treat "compounded" as a safety conclusion. Compounded drugs are not FDA-approved, and the source, formulation, and workflow matter. Identify the actual pharmacy or outsourcing facility, the patient-specific or office-use process, storage, and the applicable policy question before putting a compounded injectable on the menu.

Clinical consent documents a medical decision. Permission to use an image for marketing is different. Keep the clinical record, photographs, messages, treatment diagram, settings, lot information, and follow-up in the appropriate medical-record system. Make marketing claims supportable and do not let a promotion imply a result that the evidence does not support.

Let coverage verify the clinical model

Do not begin with an insurance application. First be able to describe the actual entities, clinicians, locations, procedures, products, devices, product source, contractor roles, event work, and after-hours responsibility. Then compare those facts to the application, policy definitions, endorsements, exclusions, clinician and entity schedules, geographic limits, defense terms, and contracts.

Ask the carrier or broker in writing when a product, device, body area, mobile site, contractor, or service is restricted or excluded. A certificate or marketing description is not a coverage answer. The issued policy controls.

For claims-made coverage, preserve the dates on which a clinician, treatment, device, site, or entity changes. The NAIC explains that claims-made coverage generally responds under the policy in force when the claim is reported, subject to its terms and any extended reporting period. Compare the actual retroactive or prior-acts grant, known-claim and related-claim terms, notice conditions, and extended-reporting terms before assuming earlier work has a reporting path.

The final readiness test is concrete: an adverse event occurs after the supervising clinician has left. Can the practice identify the patient's clinical owner, governing protocol, accessible record, immediately available responder, referral path, actual product or settings, and policy or contract that may apply? If not, the treatment should not be treated as routine.

Sources